Table 2. Characteristics influencing CT and ET prescription in first-line treatment for patients with HR+/HER2– MBC (CT vs. ET, OR <1 preferred ET, OR >1 preferred CT).
| Univariate | Multivariate | ||||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Age group ≥60 y (Ref: <60 y) | 0.507 (0.392, 0.656) | <0.0001 | 0.435 (0.326, 0.582) | <0.0001 | |
| Comorbidity (Ref: no) | 0.754 (0.601, 0.945) | 0.0143 | 0.784 (0.608, 1.011) | 0.0605 | |
| HR status ER+/PR+ (Ref: ER+ or PR+) | 0.475 (0.373, 0.606) | <0.0001 | 0.472 (0.364, 0.611) | <0.0001 | |
| De novo stage IV (Ref: recurrent metastasis) | 4.901 (3.195, 7.518) | <0.0001 | 3.532 (2.141, 5.826) | <0.0001 | |
| DRFI ≥24 m (Ref: <24 m) | 0.505 (0.410, 0.622) | <0.0001 | 0.729 (0.571, 0.932) | 0.0115 | |
| Progression on (neo)adjuvant ETa (Ref: no) | 0.592 (0.489, 0.718) | <0.0001 | 0.699 (0.562, 0.869) | 0.0012 | |
| Metastatic sites ≥2 (Ref: 1) | 1.910 (1.576, 2.316) | <0.0001 | 1.129 (0.879, 1.450) | 0.3411 | |
| Visceral disease (Ref: no) | 1.722 (1.421, 2.087) | <0.0001 | 0.700 (0.424, 1.157) | 0.1644 | |
| Bone metastasis only (Ref: no) | 0.379 (0.302, 0.476) | <0.0001 | 0.459 (0.340, 0.621) | <0.0001 | |
| Liver metastasis (Ref: no) | 2.167 (1.666, 2.818) | <0.0001 | 2.443 (1.561, 3.823) | <0.0001 | |
| Lung metastasis (Ref: no) | 1.392 (1.132, 1.712) | 0.0017 | 1.617 (1.017, 2.569) | 0.0421 | |
a, progression on (neo)adjuvant ET was defined as prior (neo)adjuvant ET disease-free interval ≤12 months. OR, odds ratio; CI, confidence Interval.